409 related articles for article (PubMed ID: 11940113)
1. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S; Toomey D; Condron C; Bouchier-Hayes D
Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction.
Ju ST; Matsui K; Ozdemirli M
Int Rev Immunol; 1999; 18(5-6):485-513. PubMed ID: 10672498
[TBL] [Abstract][Full Text] [Related]
3. Cell death induced by the Fas/Fas ligand pathway and its role in pathology.
Waring P; Müllbacher A
Immunol Cell Biol; 1999 Aug; 77(4):312-7. PubMed ID: 10457197
[TBL] [Abstract][Full Text] [Related]
4. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
6. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
7. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
8. The Fas counterattack: cancer as a site of immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Immunol Today; 1999 Jan; 20(1):46-52. PubMed ID: 10081230
[No Abstract] [Full Text] [Related]
9. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
10. Tumor counterattack: fact or fiction?
Igney FH; Krammer PH
Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
[TBL] [Abstract][Full Text] [Related]
11. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.
Martínez-Lorenzo MJ; Alava MA; Gamen S; Kim KJ; Chuntharapai A; Piñeiro A; Naval J; Anel A
Eur J Immunol; 1998 Sep; 28(9):2714-25. PubMed ID: 9754559
[TBL] [Abstract][Full Text] [Related]
12. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Li JH; Rosen D; Sondel P; Berke G
Immunology; 2002 Mar; 105(3):267-77. PubMed ID: 11918688
[TBL] [Abstract][Full Text] [Related]
13. Fas and Fas ligand in gut and liver.
Pinkoski MJ; Brunner T; Green DR; Lin T
Am J Physiol Gastrointest Liver Physiol; 2000 Mar; 278(3):G354-66. PubMed ID: 10712254
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand-induced apoptosis as a mechanism of immune privilege.
Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
[TBL] [Abstract][Full Text] [Related]
17. Activation-induced cell death in T cells.
Green DR; Droin N; Pinkoski M
Immunol Rev; 2003 Jun; 193():70-81. PubMed ID: 12752672
[TBL] [Abstract][Full Text] [Related]
18. FADD deficiency sensitises Jurkat T cells to TNF-alpha-dependent necrosis during activation-induced cell death.
Lawrence CP; Chow SC
FEBS Lett; 2005 Nov; 579(28):6465-72. PubMed ID: 16289096
[TBL] [Abstract][Full Text] [Related]
19. Induction of tolerance using Fas ligand: a double-edged immunomodulator.
Askenasy N; Yolcu ES; Yaniv I; Shirwan H
Blood; 2005 Feb; 105(4):1396-404. PubMed ID: 15486063
[TBL] [Abstract][Full Text] [Related]
20. Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology.
Webb SD; Sherratt JA; Fish RG
Math Biosci; 2002; 179(2):113-29. PubMed ID: 12208611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
